Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life

Overview

Journal Adv Ther

Date 2016 Jul 12

PMID 27397587

Citations 8

Authors

Nizar Elleuch

Hichem Zidi

Zied Bellamine

Abdelaziz Hamdane

Mondher Guerchi

Nabil Jellazi

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic venous disease (CVD) of the lower limbs is a common problem. It is more prevalent in women than in men and has a significant impact on patients' quality of life (QoL) and on the healthcare system. The aim of this study was to evaluate the efficacy of sulodexide in adult patients with CVD of the lower limbs and its effect on patients' QoL.

Methods: Patients with CVD were treated with sulodexide [250 LSU (lipasemic units) twice daily] for 3 months in a setting of real-life clinical practice. The endpoints of this observational non-comparative, open-label prospective study were the clinical efficacy of sulodexide (evaluated by scoring objective and subjective symptoms with a Likert-type scale) and the impact of sulodexide therapy on patients' QoL [assessed using the chronic venous insufficiency quality of life questionnaire (CIVIQ)].

Results: The study included 450 patients (mean age 46.9 ± 10.5 years, range 17-78 years). A greater percentage of patients were female (65.4%). Three months of treatment with sulodexide significantly improved all objective and subjective symptoms (p < 0.0001). Overall, patients reported a significant improvement in all QoL scores (p < 0.0001). Adverse events were spontaneously reported by two patients (one case of epigastric pain and one of gastric pain with vomiting).

Conclusion: Oral sulodexide significantly improves both objective and subjective symptoms, as well as functional and psychological aspects of QoL in patients with CVD.

Funding: No funding or sponsorship was received for this study. Sponsorship for article processing charges and open access fees was provided by Alfa Wassermann.

Citing Articles

Changes of the serum properties and its effect on the endothelial cells restoration in patients with chronic venous disease treated with sulodexide.

Zielinski A, Jasinska-Suminska K, Breborowicz A, Kowalska K, Zabel M, Wysocka T J Vasc Surg Venous Lymphat Disord. 2024; 12(5):101941.

PMID: 38945361 PMC: 11523325. DOI: 10.1016/j.jvsv.2024.101941.

Sulodexide Inhibits Arterial Contraction via the Endothelium-Dependent Nitric Oxide Pathway.

Ors Yildirim N, Yildirim A, Demeli Ertus M, Dastan A, Pehlivanoglu B, Chi Y J Clin Med. 2024; 13(8).

PMID: 38673605 PMC: 11050801. DOI: 10.3390/jcm13082332.

Quality of Life in Chronic Venous Disease: Bridging the Gap Between Patients and Physicians.

Santiago F Clin Drug Investig. 2023; 43(Suppl 1):3-8.

PMID: 37162624 PMC: 10219877. DOI: 10.1007/s40261-023-01264-9.

Sulodexide Develops Contraction in Human Saphenous Vein via Endothelium-Dependent Nitric Oxide Pathway.

Doganci S, Ince M, Demeli M, Ors Yildirim N, Pehlivanoglu B, Yildirim A J Clin Med. 2023; 12(3).

PMID: 36769668 PMC: 9918083. DOI: 10.3390/jcm12031019.

Severe COVID-19-A Review of Suggested Mechanisms Based on the Role of Extracellular Matrix Stiffness.

Kerch G Int J Mol Sci. 2023; 24(2).

PMID: 36674700 PMC: 9861790. DOI: 10.3390/ijms24021187.

References

Bergan J, Schmid-Schonbein G, Smith P, Nicolaides A, Boisseau M, Eklof B . Chronic venous disease. N Engl J Med. 2006; 355(5):488-98. DOI: 10.1056/NEJMra055289. View

Belczak S, Sincos I, Campos W, Beserra J, Nering G, Aun R . Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2013; 29(7):454-60. DOI: 10.1177/0268355513489550. View

Broekhuizen L, Lemkes B, Mooij H, Meuwese M, Verberne H, Holleman F . Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12):2646-55. PMC: 2974920. DOI: 10.1007/s00125-010-1910-x. View

Eklof B, Rutherford R, Bergan J, Carpentier P, Gloviczki P, Kistner R . Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40(6):1248-52. DOI: 10.1016/j.jvs.2004.09.027. View

Reitsma S, Slaaf D, Vink H, van Zandvoort M, Oude Egbrink M . The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007; 454(3):345-59. PMC: 1915585. DOI: 10.1007/s00424-007-0212-8. View

Adiguzel C, Iqbal O, Hoppensteadt D, Jeske W, Cunanan J, Litinas E . Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Clin Appl Thromb Hemost. 2009; 15(5):501-11. DOI: 10.1177/1076029609338711. View

Raffetto J, Mannello F . Pathophysiology of chronic venous disease. Int Angiol. 2014; 33(3):212-21. View

Launois R, Reboul-Marty J, Henry B . Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res. 1996; 5(6):539-54. DOI: 10.1007/BF00439228. View

Nicolaides A . Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005; 56 Suppl 1:S11-9. DOI: 10.1177/00033197050560i103. View

10.

Martinez-Zapata M, Moreno R, Gich I, Urrutia G, Bonfill X . A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg. 2007; 35(3):358-65. DOI: 10.1016/j.ejvs.2007.08.012. View

11.

Andreozzi G . Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012; 12(2):73-81. DOI: 10.2165/11599360-000000000-00000. View

12.

Scondotto G, Aloisi D, Ferrari P, Martini L . Treatment of venous leg ulcers with sulodexide. Angiology. 1999; 50(11):883-9. DOI: 10.1177/000331979905001102. View

13.

Errichi B, Cesarone M, Belcaro G, Marinucci R, Ricci A, Ippolito A . Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004; 55(3):243-9. DOI: 10.1177/000331970405500302. View

14.

Gaddi A, Galetti C, Illuminati B, Nascetti S . Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996; 24(5):389-406. DOI: 10.1177/030006059602400501. View

15.

Luzzi R, Belcaro G, Dugall M, Hu S, Arpaia G, Ledda A . The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014; 20(6):594-9. DOI: 10.1177/1076029614533143. View

16.

Jantet G . Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002; 53(3):245-56. DOI: 10.1177/000331970205300301. View

17.

Nicolaides A, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P . Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008; 27(1):1-59. View

18.

Saviano M, Maleti O, Liguori L . Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993; 13(2):96-108. DOI: 10.1185/03007999309111538. View

19.

Lozano Sanchez F, Sanchez Nevarez I, Gonzalez-Porras J, Marinello Roura J, Escudero Rodriguez J, Diaz Sanchez S . Quality of life in patients with chronic venous disease: influence of the socio-demographical and clinical factors. Int Angiol. 2013; 32(4):433-41. View

20.

Coccheri S, Mannello F . Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2014; 8:49-65. PMC: 3879015. DOI: 10.2147/DDDT.S6762. View